A Clinician’s Guide to HCV Treatment in the Primary Care Setting PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download A Clinician’s Guide to HCV Treatment in the Primary Care Setting PDF full book. Access full book title A Clinician’s Guide to HCV Treatment in the Primary Care Setting by Sherilyn Brinkley, MSN, CRNP. Download full books in PDF and EPUB format.
Author: Sherilyn Brinkley, MSN, CRNP
Publisher: Integritas Communications
ISBN:
Category : Medical
Languages : en
Pages : 31
Get Book Here
Book Description
The ability to treat and cure hepatitis C virus (HCV) infection is one of the greatest achievements of modern medicine. The simplified guidelines and the availability of highly effective and manageable direct-acting antiviral agents (DAA) regimens make it increasingly feasible to treat uncomplicated HCV in the primary care setting. This HCV eHealth SourceTM activity was developed to empower primary care clinicians, who are ideally positioned to lead frontline efforts to achieve the worldwide goal of eliminating HCV. Practices such as universal screening for HCV, the implementation of treatment regimens, and strategies for supporting, as well as monitoring, patients post-cure will be provided.
Author: Sherilyn Brinkley, MSN, CRNP
Publisher: Integritas Communications
ISBN:
Category : Medical
Languages : en
Pages : 31
Get Book Here
Book Description
The ability to treat and cure hepatitis C virus (HCV) infection is one of the greatest achievements of modern medicine. The simplified guidelines and the availability of highly effective and manageable direct-acting antiviral agents (DAA) regimens make it increasingly feasible to treat uncomplicated HCV in the primary care setting. This HCV eHealth SourceTM activity was developed to empower primary care clinicians, who are ideally positioned to lead frontline efforts to achieve the worldwide goal of eliminating HCV. Practices such as universal screening for HCV, the implementation of treatment regimens, and strategies for supporting, as well as monitoring, patients post-cure will be provided.
Author: Clinical Guidelines Program
Publisher:
ISBN:
Category :
Languages : en
Pages : 73
Get Book Here
Book Description
This guideline on treatment of chronic hepatitis C virus (HCV) infection was developed by the New York State (NYS) Department of Health (DOH) AIDS Institute (AI) to guide primary care providers and other practitioners in NYS in treating patients with chronic HCV infection.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309438020
Category : Medical
Languages : en
Pages : 187
Get Book Here
Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309146283
Category : Medical
Languages : en
Pages : 252
Get Book Here
Book Description
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.
Author: World Health Organization
Publisher: World Health Organization
ISBN: 9789241549981
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.
Author: Irwin M. Arias
Publisher: John Wiley & Sons
ISBN: 1119436826
Category : Medical
Languages : en
Pages : 1156
Get Book Here
Book Description
Bridging the gap between basic scientific advances and the understanding of liver disease — the extensively revised new edition of the premier text in the field. The latest edition of The Liver: Biology and Pathobiology remains a definitive volume in the field of hepatology, relating advances in biomedical sciences and engineering to understanding of liver structure, function, and disease pathology and treatment. Contributions from leading researchers examine the cell biology of the liver, the pathobiology of liver disease, the liver’s growth, regeneration, metabolic functions, and more. Now in its sixth edition, this classic text has been exhaustively revised to reflect new discoveries in biology and their influence on diagnosing, managing, and preventing liver disease. Seventy new chapters — including substantial original sections on liver cancer and groundbreaking advances that will have significant impact on hepatology — provide comprehensive, fully up-to-date coverage of both the current state and future direction of hepatology. Topics include liver RNA structure and function, gene editing, single-cell and single-molecule genomic analyses, the molecular biology of hepatitis, drug interactions and engineered drug design, and liver disease mechanisms and therapies. Edited by globally-recognized experts in the field, this authoritative volume: Relates molecular physiology to understanding disease pathology and treatment Links the science and pathology of the liver to practical clinical applications Features 16 new “Horizons” chapters that explore new and emerging science and technology Includes plentiful full-color illustrations and figures The Liver: Biology and Pathobiology, Sixth Edition is an indispensable resource for practicing and trainee hepatologists, gastroenterologists, hepatobiliary and liver transplant surgeons, and researchers and scientists in areas including hepatology, cell and molecular biology, virology, and drug metabolism.
Author: Timothy P. Daaleman
Publisher: Springer
ISBN: 3319718126
Category : Medical
Languages : en
Pages : 575
Get Book Here
Book Description
This book offers a comprehensive overview to chronic illness care, which is the coordinated, comprehensive, and sustained response to chronic diseases and conditions by a range of health care providers, formal and informal caregivers, healthcare systems, and community-based resources. Using an ecological framework, which looks at the interdependent influences between individuals and their larger environment, this unique text examines chronic illness care at multiple levels and includes sections on the individual influences on chronic illness, the role of family and social networks, and how chronic care is provided across the spectrum of health care settings; from home to clinic to the emergency department to hospital and residential care facilities. The book describes the organizational frameworks and strategies that are needed to provide quality care for chronically ill patients, including behavioral health, care management, transitions of care, and health information technology. The book also addresses the changing workforce needs in health care, and the fiscal models and policies that will be required to meet the needs of this population, with a focus on sustaining the ongoing transformation in health care. This book acts as a major reference for practitioners and students in medicine, nursing, social work, allied health, and behavioral medicine, as well as stakeholders in public health, health policy, and population health.
Author: Benoît Rihoux
Publisher: SAGE
ISBN: 1412942357
Category : Reference
Languages : en
Pages : 241
Get Book Here
Book Description
This new addition to the Applied Social Research Methods series is unrivalled, it is written by leaders in the growing field of rigorous, comparative techniques.
Author: Emergency Nurses Association
Publisher: Elsevier Health Sciences
ISBN: 0323710611
Category : Medical
Languages : en
Pages : 578
Get Book Here
Book Description
NEW! Restructured table of contents presents anatomically related medical and trauma chapters sequentially for quick reference. NEW! Considerations for critical care in the ED. NEW! Considerations for the transgender patient. NEW! Section on human trafficking in the Interpersonal Violence and Abuse chapter. NEW! Section on violent risk assessment in the Workplace Violence chapter. NEW! Color photos insert visually highlights and clarifies key content. EXPANDED! Substance Abuse and Addiction Emergencies chapter covers methamphetamines, bath salts, marijuana edibles, opioid abuse/prescription drug abuse, heroin/Narcan, and substance abuse disorder. EXPANDED! Chapter on end-of-life includes information on palliative care considerations. UPDATED! Infectious Diseases chapter addresses coronavirus 19 (COVID-19), Ebola, and vector-borne malaria.
Author:
Publisher: World Health Organization
ISBN: 9240019006
Category : Medical
Languages : en
Pages : 76
Get Book Here
Book Description
WHO approved more hepatitis direct-acting antivirals (DAAs) for the treatment of infection with the hepatitis C virus (HCV) by 2020 which helped low- and middle-income countries increase the number of registered treatments, reduce prices of a full treatment under US$100 – update is as low as $60 for three months, and strive towards hepatitis C elimination. For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pharmaceutical products, including product pricing, the regulatory environment and patent status, which together shape the national hepatitis response in different settings. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners. Globally, at the end of 2017, only 5 million – or 7% – of the 71 (62–79) million people chronically infected with HCV had cumulatively received treatment with DAAs. As countries continue to tackle the disease burden and service disruptions caused by the COVID-19 pandemic, it is critical to ensure that the recent momentum and gains in the response to hepatitis C are not lost. Against this backdrop, this report is a strong reminder to continue to invest in building resilient and sustainable health systems that are focused on universal health coverage.
